Q-omics provides the consensus-scored PRXL2AP1 profile across patient tissues and cancer cell-line models. PRXL2AP1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRXL2AP1 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, PRXL2AP1 RNA expression shows 11,423 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, PRAD, and LSCC as cancer lineages where PRXL2AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRXL2AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRXL2AP1 survival associations across molecular data types. PRXL2AP1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRXL2AP1 RNA expression–survival associations across cancer types. High PRXL2AP1 expression shows unfavorable associations in KIRP, KIRC, PAAD, KICH, UCEC and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRXL2AP1 RNA expression.
This table summarizes PRXL2AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRXL2AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRXL2AP1 shows higher tumor expression in PRAD, HNSC and LUSC. The PRAD box plot shows higher PRXL2AP1 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .016).
This table shows molecular features associated with PRXL2AP1 in patient tissues and cancer cell lines. In patient samples, PRXL2AP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
